Afuco™ Anti-Human CTSS ADCC Therapeutic Antibody (Fsn0503h), ADCC Enhanced
Anti-CTSS ADCC Enhanced Antibody (Fsn0503h) is an ADCC enhanced antibody produced by our Afuco™ platform. Fsn0503h is a fully human anti-Cathepsin S antibody with anti-tumour and anti-angiogenic properties. Cathepsin S is a cysteine protease highly expressed in many cancers including colorectal, breast, prostate and glioblastoma's. It is involved in tumour progression through extracellular matrix remodelling. Fusion Therapeutics has generated positive preclinical data demonstrating efficacy of Fsn0503h in multiple models both as a monotherapy and in combination with approved agents.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-186CL |
| Pricing | Inquiry |
| Host | Human |
| Target | CTSS |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | ≥1 year at -20°C. If the reconstituted antibody cannot be used within two weeks, it should be aliquoted into smaller vials and stored at -20°C |